

Cover Story
Free
By Matthew Bin Han Ong
FDA has created a framework for evaluating the use of real-world evidence to support additional indications for already approved drugs as well as to satisfy drug post-marketing study requirements.
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for January
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

















